What are options for my patients with erectile dysfunction who have an unsatisfactory response to PDE5 inhibitors?

ED MANAGEMENT: GENERAL CONSIDERATIONS

Before medical therapy for ED is tried, it is crucial to address modifiable risk factors, counsel patients on lifestyle modifications, and identify any medications or underlying medical conditions contributing to ED. Risk factors for ED include smoking, obesity, cardiovascular disease, depression, prostate surgery, penile trauma, obstructive sleep apnea, and testosterone deficiency. Lifestyle adjustments such as weight loss, increased cardiovascular exercise, reduced alcohol intake, and quitting smoking can partially alleviate symptoms.¹ Also, a thorough history should explore psychological, psychosocial, and relational factors and sexual practices that may be impacting sexual performance, and referral to a sex therapist should be considered.

A diagnosis of ED can indicate the presence of systemic disease or reversible causes like medication side effects or testosterone deficiency (discussed below). When certain medications such as antidepressants or antihypertensives are suspected of contributing to ED,³ the patient should be advised to talk with the prescribing physician to determine whether alternative medications with better side-effect profiles are available.

Beta-blockers are associated with ED, although the etiology is not well established.⁴ Patient awareness or anxiety regarding ED as a potential side effect of beta-blockers may itself contribute to dissatisfaction with erectile function after starting a beta-blocker. While further study is needed, trying an alternative medication for patients on first-generation (propranolol) or second-generation (metoprolol, atenolol) beta-blockers may be considered. In a review of several small studies, Sharp and Gales⁵ noted mildly improved or similar sexual function in patients after starting nebivolol, which was attributed to the beta-blocker’s ability to stimulate endothelial release of nitric oxide, producing vasoactive effects and potentiating penile erection.

If feasible for the patient, medications like calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers can also be explored, as their risk for causing ED is thought to be lower. Thiazide diuretics at high doses have been associated with adverse effects on erectile function compared with other antihypertensive drugs.⁶ However, treatment of hypertension should remain the priority, and it may not be clinically appropriate to adjust antihypertensive medications, particularly without strong evidence to support the use of 1 medication over another.

The evidence regarding a correlation between statin medications and ED risk is conflicting. Some studies suggest that statins have sexual side effects, while others propose that the overall cardiovascular benefit of these medications contributes to improved erectile function.⁷ No large-scale randomized controlled trials have established a link between statins and testosterone levels, and cessation of statin therapy or lowering of statin regimens as a means of improving ED is not recommended. Rather, we suggest optimizing well-established contributing factors such as cardiovascular fitness and testosterone levels.

PHOSPHODIESTERASE TYPE 5 INHIBITORS

Despite making lifestyle changes, many patients with ED require PDE5 inhibitors such as sildenafil or tadalafil to improve erectile function. These agents promote erections by increasing nitric oxide levels and blocking the decomposition of cyclic guanosine monophosphate, thereby relaxing the smooth muscle within the corpora cavernosa and increasing blood flow.¹ However, PDE5 inhibitors are efficacious in only 60% to 70% of patients.²

When starting PDE5 inhibitors, proper administration should be ensured, as a large proportion of treatment failures with these agents is attributed to incorrect use.² Sildenafil should be taken 30 to 60 minutes before intercourse on an empty stomach. The recommended window for taking on-demand tadalafil, which is not impacted by food intake, is 30 to 120 minutes before intercourse, but for optimal effectiveness, it should be taken 60 to 120 minutes before intercourse.⁸ Daily low-dose tadalafil (5 mg) may be considered for men who also experience voiding dysfunction due to prostate enlargement or men with mild ED.

Patients taking 5-alpha-reductase inhibitors for benign prostatic hyperplasia who also experience ED and low libido should be referred to a urologist for alternative management strategies such as daily low-dose tadalafil, alpha-blockers, or minimally invasive surgical therapies. In fact, some selective alpha-blockers have been found to preserve or improve erectile function.⁹ Combination therapy with daily tadalafil plus on-demand higher-dose tadalafil or sildenafil may be considered.¹⁰

Before determining that the medication has failed to achieve the desired result, several trials of PDE5 inhibitors with at least 24 hours between doses should be attempted.¹¹ Additionally, other reversible causes of ED, such as testosterone deficiency, should be assessed. An early morning testosterone level (before 11:00 am) can identify testosterone deficiency in the presence of symptoms or signs of low testosterone such as low libido, fatigue, and loss of body hair.¹⁰ Testosterone levels less than 300 ng/dL with these accompanying symptoms may warrant treatment with testosterone replacement therapy, which placebo-controlled randomized trials and meta-analyses have demonstrated may help improve erectile function and libido.^10–12 However, patients with ED but no symptoms of testosterone deficiency are less likely to benefit from replacement therapy. Assessment of testosterone deficiency is most valuable in men with borderline response to PDE5 inhibitors and with other signs and symptoms of low testosterone.

Once these avenues have been exhausted, exploring alternative therapies that aid in restoring erectile function should be considered.

OTHER THERAPEUTIC OPTIONS

Therapeutic options beyond PDE5 inhibitors include intracavernosal injection therapy, vacuum erection devices, and penile prostheses.^1,2,11 These alternatives are typically used when the patient does not respond to PDE5 inhibitors or experiences intolerable side effects (eg, headache, flushing, dyspepsia, visual disturbances, backache) from them. Treatment should be based on patient and partner preferences, comorbidities, and current medications.² The 2018 American Urological Association guideline on ED¹¹ emphasizes the importance of shared decision-making between patient and physician. In this process, the physician presents the various treatment options to the patient, and the risks and benefits of each are discussed before the treatment most aligned with patient goals and expectations is determined.

SHOCKWAVE THERAPY

The mechanism of action of low-intensity extracorporeal shockwave therapy (Li-ESWT) in treating ED is unclear. It is hypothesized that extracorporeal shockwaves stimulate expression of endothelial nitric oxide synthase, vascular-endothelial growth factor, and other vascular growth factors, promoting vessel expansion and neovascularization that promote blood flow and erectile function.²³ The Sexual Medicine Society of North America regards Li-ESWT as promising but does not endorse its use beyond research given its novelty.²⁴ Since the release of this statement, further studies have demonstrated some efficacy of Li-ESWT in men with moderate ED, though an optimal protocol remains to be determined.²⁵

It is important to differentiate between Li-ESWT and radial wave therapy, the latter of which uses low-pressure acoustic waves to deliver lower energy with less tissue penetrance compared with Li-ESWT.²⁶ Direct-to-consumer marketing from men’s health clinics often use these 2 terms interchangeably even though a randomized controlled trial found no difference between radial wave therapy and sham therapy for treating ED.²⁶ The Sexual Medicine Society of North America corroborates this, drawing a distinction between Li-ESWT and radial wave therapy.²⁴ While regenerative therapies such as Li-ESWT in ED treatment require further investigation, patients should be informed regarding the lack of evidence to support radial wave therapy for ED treatment, particularly as radial wave therapy devices are often promoted as equivalent by health clinics for men.

WHAT NOT TO OFFER

Stem cell therapy was initially proposed to improve erectile function by promoting angiogenesis and tissue healing and reducing scarring, inflammation, and apoptosis.²⁷ Clinical trials have been limited, and its clinical application is still unknown. Similarly, platelet-rich plasma injections have been studied as an option for ED, but a recent randomized controlled trial found no difference in efficacy between platelet-rich plasma and placebo.²⁸ Thus, the Sexual Medicine Society of North America’s position is that stem cell and platelet-rich plasma therapies should not be used in clinical practice.²⁴

DISCLOSURES

Dr. Bajic has disclosed serving as an advisor or review panel participant for Endo Pharmaceuticals, Inc. The other authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.